Aurobindo Pharma Ltd (BOM:524804)
₹ 1267.4 -20.45 (-1.59%) Market Cap: 736.11 Bil Enterprise Value: 739.33 Bil PE Ratio: 21.08 PB Ratio: 2.49 GF Score: 91/100

Full Year 2019 Aurobindo Pharma Ltd Earnings Call Transcript

May 29, 2019 / 03:00AM GMT
Release Date Price: ₹685.6 (+1.41%)
Operator

Good day, ladies and gentlemen, and welcome to the Q4 FY '18-'19 Earnings Conference Call of Aurobindo Pharma Limited. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Krishna Kiran, Investor Relations. Thank you, and over to you, sir.

Krishna Kiran
Aurobindo Pharma Limited - IR Officer

Thank you, Nashid. Good morning and a warm welcome to our fourth quarter and full year FY '19 earnings call. I am Krishna Kiran from Aurobindo Pharma Investor Relations. We hope you have received the Q4 financials and the press release that we have sent out yesterday. These are also available on our website.

With me, we have our senior management team, represented by Mr. N. Govindarajan, Managing Director; Sanjeev Dani, COO, Head Formulations; Mr. Santhanam Subramanian, CFO; Mr. Swami Iyer, CFO, Aurobindo Pharma USA. We will begin the call with summary highlights from the management, followed by an interactive Q&A session.

Please note that some of the matters we will discuss today are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot